Meeting
2018 ASCO Annual Meeting
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
Authors
David M. O'Malley
The Ohio State University College of Medicine, Columbus, OH
David M. O'Malley , Lainie P. Martin , Lucy Gilbert , Ignace Vergote , Ursula A. Matulonis , Michael J. Birrer , Cesar Martin Castro , Karim S. Malek , Antonio González-Martín , Kathleen N. Moore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02606305
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5549)
DOI
10.1200/JCO.2018.36.15_suppl.5549
Abstract #
5549
Poster Bd #
276
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.
First Author: David M. O'Malley
First Author: David M. O'Malley
Poster
2022 ASCO Annual Meeting
PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer.
First Author: Judith Michels
Poster
2021 ASCO Annual Meeting
Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
First Author: Judith Michels